Lonza Offers to Acquire Patheon

Lonza says it has submitted a non-binding proposal to acquire all of the outstanding restricted voting shares of leading pharmaceutical contract manufacturing and development services company Patheon (Toronto) at a price of $3.55/share. The price offered by Lonza is significantly higher than the offer made by private equity firm JLL of $2/share, say press reports. “An acquisition of Patheon would take us into the complementary activities of finished dosage development and manufacturing for both small molecule and biological active ingredients,” says...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers